The company commenced its operations in 2021 with the production of highly pathogenic avian influenza (HPAI) vaccines, swiftly addressing 70% of the national demand for this vaccine within industrial poultry farms. Since its establishment, Nova Vaccine Rad has expanded its product portfolio to include bivalent vaccines for Newcastle disease and avian influenza (H9N2 + V4), bivalent Newcastle-influenza vaccines (H9N2 + NDG7), monovalent influenza vaccine (H9N2), monovalent Newcastle vaccine (G7), as well as trivalent vaccines such as (Newcastle – Avian Influenza – IBD) and (Avian Influenza – Newcastle with two strains, G VII + G IV). Additionally, the company is actively progressing in the development of other inactivated poultry vaccines. Through these innovations, Nova Vaccine Rad has established itself as one of the leading and most reputable companies in Iran’s poultry vaccine industry. In addition, Nova Vaccine Rad has made significant progress in enhancing vaccine efficacy through the production of oil adjuvants for poultry vaccines. By leveraging cutting-edge technology and high-quality raw materials, the company has developed low-viscosity oil-based adjuvants that are easy to inject and highly effective in industrial poultry farms. Furthermore, Nova Vaccine Rad became the first company in Iran to successfully export these products abroad, further cementing its reputation for quality and innovation in the global vaccine industry.

As part of its ongoing commitment to quality and innovation, Nova Vaccine Rad continues to expand its operations to meet the growing needs of both the domestic and international poultry industry. With its highly skilled team and advanced technical expertise, the company plays a key role in improving the health and safety of poultry both within Iran and internationally.